Healthy Skepticism Library item: 11979

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Imbs JL, Welsch M.
[Clinical assessment of drug safety].
Ann Pharm Fr 2007 Sep; 65:(5):298-302
http://www.masson.fr/masson/portal/bookmark?Global=1&Page=18&MenuIdSelected=106&MenuItemSelected=0&MenuSupportSelected=0&CodeProduct4=260&CodeRevue4=APF&Path=REVUE/APF/2007/65/5/ARTICLE11942567983.xml&Locations=

Abstract:

The environment of drug safety is changing. In addition to the current system of pharmacovigilance based on spontaneous report of adverse events, clinical data observed in a given patient with a given symptom is taken into consideration and compared with information coming from pharmacovigilance data bases, which is then analyzed for causality by the experts of both the promotor and the public network. Such information is integrated into a risk management strategy, defined together by the French drug agency (Afssaps) and the marketing authorization holder. This strategy includes a pharmacovigilance plan and, if possible, a risk minimisation plan.

Keywords:
Pharmacovigilance, Risk management, Drug, Adverse effect PMID: 17982376 [PubMed - in process]

Notes:

[Article in French]